相似文献
1
Dilemmas in treating smoldering multiple myeloma.
J Clin Oncol. 2015 Jan 1;33(1):115-23. doi: 10.1200/JCO.2014.56.4351. Epub 2014 Nov 24.
2
Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
Curr Hematol Malig Rep. 2016 Apr;11(2):102-10. doi: 10.1007/s11899-016-0305-6.
3
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Oncologist. 2016 Mar;21(3):333-42. doi: 10.1634/theoncologist.2015-0303. Epub 2016 Feb 26.
4
Understanding high-risk smoldering multiple myeloma.
Leuk Lymphoma. 2023 Jul-Aug;64(8):1361-1372. doi: 10.1080/10428194.2023.2216818. Epub 2023 May 25.
5
Smoldering multiple myeloma.
Blood. 2015 May 14;125(20):3069-75. doi: 10.1182/blood-2014-09-568899. Epub 2015 Apr 2.
6
The road to treating smoldering multiple myeloma.
Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S59-64. doi: 10.1016/j.clml.2014.04.012.
7
[Smoldering multiple myeloma].
Rev Med Interne. 2014 Apr;35(4):243-9. doi: 10.1016/j.revmed.2013.08.004. Epub 2013 Sep 17.
8
Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
Leuk Lymphoma. 2015 Jan;56(1):34-41. doi: 10.3109/10428194.2014.897702. Epub 2014 Mar 25.
9
Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
Leuk Lymphoma. 2018 Feb;59(2):288-299. doi: 10.1080/10428194.2017.1334124. Epub 2017 Jun 8.
10
New approaches to smoldering myeloma.
Curr Hematol Malig Rep. 2013 Dec;8(4):270-6. doi: 10.1007/s11899-013-0174-1.
引用本文的文献
1
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article.
Blood Lymphat Cancer. 2023 Sep 15;13:33-57. doi: 10.2147/BLCTT.S272703. eCollection 2023.
2
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.
3
What Is New in the Treatment of Smoldering Multiple Myeloma?
J Clin Med. 2021 Jan 22;10(3):421. doi: 10.3390/jcm10030421.
4
Shall we treat smoldering multiple myeloma in the near future?
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):194-204. doi: 10.1182/asheducation-2017.1.194.
5
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.
Clin Cancer Res. 2016 Nov 15;22(22):5428-5433. doi: 10.1158/1078-0432.CCR-16-0866.
6
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
Bone Marrow Transplant. 2016 Dec;51(12):1565-1568. doi: 10.1038/bmt.2016.222. Epub 2016 Sep 5.
7
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
Immunol Rev. 2016 Mar;270(1):95-112. doi: 10.1111/imr.12389.
8
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.
Leukemia. 2016 Feb;30(2):417-22. doi: 10.1038/leu.2015.291. Epub 2015 Oct 22.
9
The road to cure in multiple myeloma starts with smoldering disease.
Expert Opin Orphan Drugs. 2015 Apr 12;3(6). doi: 10.1517/21678707.2015.1036740.
10
Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Epub 2015 Jan 27.
本文引用的文献
1
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
Am J Hematol. 2014 Dec;89(12):1159-60. doi: 10.1002/ajh.23831.
2
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.
J Clin Oncol. 2014 Jul 10;32(20):2173-80. doi: 10.1200/JCO.2013.53.0329. Epub 2014 Jun 2.
3
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21.
4
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
Blood. 2014 May 15;123(20):3073-9. doi: 10.1182/blood-2014-01-550020. Epub 2014 Mar 19.
5
Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.
Leukemia. 2014 Sep;28(9):1902-8. doi: 10.1038/leu.2014.75. Epub 2014 Feb 18.
6
Serial exome analysis of disease progression in premalignant gammopathies.
Leukemia. 2014 Jul;28(7):1548-52. doi: 10.1038/leu.2014.59. Epub 2014 Feb 5.
7
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.
8
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.
9
International Myeloma Working Group recommendations for global myeloma care.
Leukemia. 2014 May;28(5):981-92. doi: 10.1038/leu.2013.293. Epub 2013 Oct 9.
10
Treatment for high-risk smoldering myeloma.
N Engl J Med. 2013 Oct 31;369(18):1762-3. doi: 10.1056/NEJMc1310911.
Zotero 插件